A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

  • Perkins, Andrew (Primary Chief Investigator (PCI))
  • Leahy, Michael F (Chief Investigator (CI))
  • Ross, David Morrall (Chief Investigator (CI))
  • Prasad, Ritam (Chief Investigator (CI))
  • Kennedy, Nola (Project Manager)
  • Choi, Philip (Chief Investigator (CI))

Project: Research

Project Details

Effective start/end date5/02/2031/12/25


  • Clinical Haematology
  • Myelofibrosis
  • Clinical trial